Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]

Détails

Ressource 1Télécharger: RMS_696_1165 (1).pdf (154.20 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_A124D4D50BD9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Arangalage D., Pavon A.G., Hugelshofer S., Desgraz B., Tzimas G., Delyon J., Muller O., Obeid M., Ribi C., Michielin O., Özdemir B.C., Monney P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
03/06/2020
Peer-reviewed
Oui
Volume
16
Numéro
696
Pages
1165-1168
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology, by reshaping the prognosis of many cancers and are progressively becoming the standard of care. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), of which cardiovascular irAEs are particularly feared. ICI-induced myocarditis is often a diagnostic challenge because of the vast heterogeneity of clinical presentations, and it is associated with a high mortality rate of around 50%. The present article summarizes the cardiac manifestations, the diagnostic strategy and the therapeutic management of patients with ICI-induced myocarditis used in the treatment of cancer.
Mots-clé
Cardiotoxicity/etiology, Humans, Immunotherapy/adverse effects, Myocarditis/chemically induced, Neoplasms/drug therapy, Neoplasms/immunology, Neoplasms/pathology
Pubmed
Création de la notice
10/06/2020 19:47
Dernière modification de la notice
20/08/2022 6:12
Données d'usage